News Releases

<< Back
Waters Expands Mass Spectrometry Boundaries with Introduction of Next- Generation, Upgradeable SYNAPT Platform

New SYNAPT MS System is the only mass spectrometer that is 'HDMS-ready' to
meet current and future needs

MILFORD, Mass., Jan. 21 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT) today launched the Waters(R) SYNAPT(TM) MS system, a next- generation quadrupole acceleration, time-of-flight (oa-Tof) mass spectrometry (MS) platform. SYNAPT MS is a key part of Waters' strategy to enhance the quality and productivity of life science and drug discovery and development workflows.

Additionally, the SYNAPT MS system is the only platform which provides an upgrade pathway to the SYNAPT High Definition MS(TM) (HDMS(TM)) system, uniquely enabling researchers to analyze samples differentiated by size, shape and charge, as well as mass, ultimately providing new capabilities that can help them meet and exceed future requirements.

"Confident sample identification, detailed characterization and increased productivity are primary requirements for intelligent mass spectrometry based solutions in key biomedical applications such as proteomics, metabonomic profiling, biomarker discovery/validation and pharmaceutical R&D," said Brian W. Smith, Vice President, Mass Spectrometry Operations for the Waters Division. "The new SYNAPT MS meets these demands through application specific system solutions designed to help our customers accelerate and improve the quality of laboratory analysis with the goal of advancing research and reducing time-to-market."

SYNAPT MS is a central component of Waters' system level solutions - combining ACQUITY UltraPerformance LC(R) (UPLC(R))separations, Exact Mass MSE data acquisition and 'chemically intelligent' MassLynx(TM) Informatics - designed to generate high quality, comprehensive data from complex biological samples, maximize confidence in results and enable scientists to make better informed decisions.

SYNAPT MS Systems also offer unparalleled versatility and flexibility. For example, the MALDI-enabled SYNAPT MS system enables researchers to perform MALDI imaging studies, primarily to determine the spatial localization of drugs, metabolites and peptides in biological tissues with high specificity and sensitivity. This can enable greater numbers of candidates to be evaluated in the drug discovery phase, leading to more rigorous selection of compounds for ongoing development.

"A unique aspect of the SYNAPT MS System is that it is 'HDMS-ready.' Our customers will be able to upgrade their systems to incorporate the unique High Definition MS capabilities when they require more powerful solutions to meet their future goals, effectively future-proofing their laboratories," added Smith.

Waters SYNAPT HDMS

Designed for leading researchers working at the boundaries of conventional mass spectrometry capabilities who need to further characterize and define their samples, Waters SYNAPT HDMS systems offer unique, enabling functionality. Using Waters' patented TriWave(TM) technology, SYNAPT HDMS systems combine high-efficiency, ion mobility-based, measurements and separations with high-performance quadrupole, time-of-flight mass spectrometry. SYNAPT HDMS systems enable researchers to differentiate molecules by size, shape and charge, as well as mass, and to deliver increased specificity and sample definition beyond that achievable by conventional mass spectrometers.

Recently, Swedish-based biotechnology firm Medivir AB chose the SYNAPT HDMS System to hasten its drug discovery efforts in the area of protease inhibitor research and eventually help patients who suffer with herpes, hepatitis C, HIV, osteoporosis, osteoarthritis, and high blood pressure. "The sensitivity of this instrument is significantly greater than the average quadrupole time-of-flight instrument and gives us more complete metabolic profiles," says Kurt Benkestock, Senior Research Scientist, Analytical Chemistry Department, who supports many of Medivir's research efforts. "At one time, we relied on outside resources to give us the information we needed. Now with the SYNAPT HDMS System, we can acquire the data we need in house and move candidates into advanced development phases faster."

Additionally, the University of Leeds' Astbury Centre for Structural Molecular Biology has published the results of protein research conducted with its newly-acquired SYNAPT HDMS System in the Journal of the American Society of Mass Spectrometry. Researchers at Leeds describe the successful separation and analysis of various folded forms of the proteins cytochrome c and beta-2- microglobulin, an achievement the Ashcroft Laboratory hopes will lead to a more complete understanding of the biological processes responsible for amyloid fibril formation, bacterial pilus aggregation and virus capsid assembly - all associated with debilitating diseases including Alzheimer's, Creuzfeldt-Jakob's, and Parkinson's disease.

Finally, the University of California, Davis, recently announced that it is currently using the SYNAPT HDMS system to study eukaryotic translation, the process by which messenger RNA is translated into proteins within the human 40S ribosome, to better understand how infectious diseases like hepatitis C and polio are transferred to humans.

At PITTCON(R) 2007, the Waters SYNAPT High Definition MS System received the PITTCON Editor's Gold Award as Best New Product as well as Instrument Business Outlook newsletter's top prize for best new product. For more information on Waters SYNAPT High Definition MS System, visit www.waters.com/HDMS.

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE: WAT) creates business advantage for laboratory- dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.28 billion in 2006 and 4,700 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters, SYNAPT, SYNAPT HDMS, HDMS, High Definition MS, High Definition Mass Spectrometry, LCT Premier XE, UltraPerformance LC, UPLC, ACQUITY, Triwave and MassLynx are trademarks of Waters Corporation. Pittcon is a registered trademark of the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy.

Media Contact:
Brian J. Murphy
Waters Corporation
Public Relations Manager
508-482-2614
Brian_J_Murphy@waters.com

SOURCE Waters Corporation